Norwegian biotech company SoftOx Solutions AS (Euronext Growth Oslo:SOFTX) announced on Tuesday that the first patient has been recruited to SBE-01, the clinical study of its wound treatment agent.
The study team has now been able to screen and select several patients for the study, said Glenn Gundersen, chief medical officer of SoftOx.
SBE-01 is a first-in-human (phase I) study with the SoftOx's lead wound care product, SBE, which is designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE to help develop the product into an effective infection-treatment solution in problematic, non-healing wounds.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study